Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Corcept Therapeutics Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 29,000 0 0 3.31M 10.36M
Cost of Goods Sold (COGS) incl. D&A - 6,000 3,000 91,000 143,000
COGS excluding D&A - 0 0 64,000 69,000
Depreciation & Amortization Expense 10,000 6,000 3,000 27,000 74,000
Depreciation 10,000 6,000 3,000 27,000 74,000
Amortization of Intangibles - - - 0 0
Gross Income - (6,000) (3,000) 3.22M 10.21M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 20.27M 27.43M 32.33M 39.49M 51.71M
Research & Development 14.4M 18.95M 21M 14.07M 20.47M
Other SG&A 5.87M 8.48M 11.33M 25.41M 31.24M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 0 0 0 0
EBIT after Unusual Expense 0 0 0 0 0
Non Operating Income/Expense (17,000) (25,000) (25,000) 0 (115,000)
Non-Operating Interest Income 101,000 1.5M 3,000 0 0
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense - 0 0 1.78M 4.4M
Gross Interest Expense - 0 0 1.78M 4.4M
Interest Capitalized 0 - - 0 0
Pretax Income (20.17M) (25.97M) (32.35M) (38.05M) (46.01M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 - 0 0 0
Consolidated Net Income (20.17M) (25.97M) (32.35M) (38.05M) (46.01M)
Minority Interest Expense 0 0 0 0 0
Net Income (20.17M) (25.97M) (32.35M) (38.05M) (46.01M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - - - 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (20.17M) (25.97M) (32.35M) (38.05M) (46.01M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (20.17M) (25.97M) (32.35M) (38.05M) (46.01M)
EPS (Basic) (0.38) (0.38) (0.39) (0.41) (0.46)
Basic Shares Outstanding 52.44M 68.34M 83.31M 93.02M 99.82M
EPS (Diluted) (0.38) (0.38) (0.39) (0.41) (0.46)
Diluted Shares Outstanding 52.44M 68.34M 83.31M 93.02M 99.82M
EBITDA (20.24M) (27.43M) (32.33M) (36.25M) (41.42M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.